This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. Background: Xenotropic murine leukemia virus-related virus (XMRV) is a gamma retrovirus, which has been detected in patients with prostate cancer, chronic fatigue syndrome, and general population with a number of acquired infections such as infection with human T-cell lymphotropic virus (HTLV) and human immunodeficiency virus (HIV). The aim of this study was to determine the HTLV-1 and XMRV coinfection for the first time in Iranian patients who were admitted to the Tehran hospitals. Materials and Methods: Two hundred and ninety one patients suspected with HTLV-1 were referred to the hospitals affiliated to the Iran University of Medical Sciences, Tehran, Iran from April 2012 to October 2016. Genomic deoxyribonucleic acid (DNA)/ribonucleic acid (RNA) from peripheral blood mononuclear cells/cerebrospinal fluids was extracted by High Pure Viral Nucleic Acid Kit (Roche, Germany). After complementary DNA synthesis, conventional reverse transcriptase polymerase chain reaction was used for the detection of HTLV-1 or XMRV-infected patients. Statistical Package for Social Sciences (SPSS) software, version 16 (SPSS, Chicago, IL, USA) was used for statistical analyses. Results: Of the 291 patients suspected of HTLV infection, 123 (42.3%) were male with a mean age of 38 ± 15 years. HTLV-1 RNA was found in 93 (31.9%) specimens comprising 40 men (41.3%) and 53 women (56.9%). Of the 93 patients who were HTLV-1 positive, one sample (1%) was positive for XMRV env gene. Conclusion: These findings suggest that the lack of significant detection of XMRV in patients who were HTLV-1 positive could not be associated with complications of HTLV-1. Although this is a preliminary report from Iranian patients with HTLV-1, further studies are needed to show the actual prevalence of XMRV infection by geographical distribution and various populations.
R etroviruses are single-stranded, positivesense ribonucleic acid (RNA) viruses with a deoxyribonucleic acid (DNA) intermediate, which have been frequently isolated from a wide variety of animal species and have been shown to be associated with a wide range of diseases from neoplastic/non-neoplastic hematological malignancies and inflammatory diseases to immunodeficiencies, neurodegenerative diseases, and respiratory syndromes. [1] [2] [3] Xenotropic murine leukemia virus-related virus (XMRV) is a class of endogenous gamma retroviruses that were identified rarely in patients with prostate cancer. It has been thought to be the first gamma retrovirus infecting humans. Some studies have detected XMRV not only in patients with chronic fatigue syndrome (CFS) and prostate cancer but also in 1%-7% of healthy controls tested in the same studies. [2, [4] [5] [6] As some studies have found XMRV in up to 87% of patients and others have failed to detect XMRV infection either in the patient cohorts or in the general population, the correlation between XMRV and human diseases has remained controversial. [7] [8] [9] Human T-cell lymphotropic virus type 1 (HTLV-1) is an oncogenic human retrovirus and was primarily reported in 1980. [3, 10, 11] This retrovirus causes a range of diseases with different clinical outcomes such as adult T cell leukemia/lymphoma and inflammatory neurologic disease. HTLV-1 infection might also be associated with other autoimmune disorders such as Sjogern's syndrome, polymyositis, inflammatory arthritis, and uveitis. Although the pathophysiology of these disorders has not been fully understood, immunovirological factors appear to play crucial roles. [3, 12, 13] Blood or other body fluids are the shared routes of transmission for all four known human retroviruses: human immunodeficiency virus (HIV)-1, HIV-2, HTLV-1, and HTLV-2. [1, 14, 15] To date, no definitive route of transmission has been found for XMRV. [16, 17] Some studies have suggested that XMRV could be associated with HTLV-infected individuals and this virus may be associated with a range of disorders. [1, 12, 18] In this regard, the aim of this study was to detect HTLV-1 and XMRV coinfection in Iranian samples using reverse transcriptase polymerase chain reaction (RT-PCR) technique.
MAterIAls And Methods

Sample collection and processing
In this cross-sectional study, the patients suspected of HTLV-1 symptoms were referred to hospitals affiliated to the Iran University of Medical Sciences, Tehran, Iran, as practitioner diagnosed and enrolled them from April 2012 to October 2016. Written informed consent was obtained from each patient. The ethics of the study followed the guidelines of the ethical committee of the Iran University of Medical Sciences. This study included patients who had symptoms of HTLV-1 involvement (malignancy, neurological disease, strongyloidiasis, and bronchiectasis). Patients who did not meet the inclusion criteria were excluded. Five milliliters of peripheral blood was collected from 127 patients into sterile ethylenediaminetetraacetic acid (EDTA)-containing Vacutainer tubes. After centrifugation, peripheral blood mononuclear cells (PBMCs) were isolated from the whole blood (WB) samples by using Ficoll separation method (Lympholyte H; Cedarlane, Hornby, Canada). [19] [20] [21] Briefly, the isolated PBMCs were washed three times with phosphate-buffered saline, and then the cells were resuspended in 200 μL of RNAlater solution (Ambion, Austin, TX). Furthermore, 2.5 mL sample of cerebrospinal fluid (CSF) was taken from 164 patients and stored without any preservatives and was directly used to further the extraction procedure. All specimens were stored at −80°C until use.
Ribonucleic acid isolation
Total DNA/RNA was isolated via the High Pure Viral Nucleic Acid Kit (Roche, Germany). Briefly, 200 μL of PBMC or CSF was used for RNA purification, according to protocol. [20, 22] Then, eluted RNA quantity and purity were evaluated using a NanoDrop ND-1000 (Thermo Scientific, Wilmington, DE) spectrophotometer. Extracted mix was stored at −20°C until use.
Complementary deoxyribonucleic acid synthesis RNA in the total nucleic acid isolates was reverse transcribed to complementary DNA (cDNA) by random hexamers as primers and M-MuLV reverse transcriptase, according to the manufacturer's instructions. [19, 23] Then, the cDNA was checked for quality using the NanoDrop ND-1000 (Thermo Scientific). Total mix was stored at −20°C and was used for further analysis by PCR. Reverse transcriptase polymerase chain reaction Two separate conventional RT-PCRs were performed for the amplification of env and tax genes of XMRV and HTLV-1, respectively. The primers previously described were used for molecular detection via RT-PCR technique for these two targets [ Table 1 ]. [24, 25] A total volume of 25 μL reaction mixture consisted of a 5-μM concentration of cDNA samples or controls, a deoxyribonucleoside triphosphates (dNTPs) mix (Fermentas, Germany) with equal concentrations of each of the four dNTPs at a 1 mM concentration, each of forward and reverse primers at 1 μM concentration, MgCl 2 solution (Fermentas) at 1 μM concentration, 2.5 μM concentration PCR buffer 10x (Fermentas), and 0.5 units/μL concentration of Taq DNA polymerase (Fermentas), and sterilized distilled water was added to round out the total volume.
A Bio-Rad (T100 Thermal Cycler) thermo cycler was used for PCR with the following program: one cycle of initial denaturation at 95°C for 5 min; 35 cycles of denaturation at 95°C for 30 s; annealing at 51°C and 56°C for 30 s for XMRV and HTLV-1, according to the primers melting temperature, respectively; extension at 72°C for 30 s, according to the length of the product; and finally, one cycle of final extension at 72°C for 5 min. Positive controls for HTLV-1 and XMRV were the MT-2 cell line DNA and XMRV-infected LNCaP cell DNA, respectively. Finally, the PCR products were visualized by gel electrophoresis in a 1.5% agarose gel stained with ethidium bromide.
Quantitative real-time polymerase chain reaction SYBR™ Green real-time PCR was performed for viral load assay and quantified in the Rotor-Gene-Q 6000 thermocycler (Corbett, Australia). A total of 15 μL reaction mix composed of 7.5 μL of 2× Amplicon III mix (Odense M, Denmark), 0.5 μL of each forward and reverse primers corresponding to 0.5-μM concentration, and 3 μL each sample or control corresponding to 0.2-0.5 μM concentration. Primer sequences were obtained from an earlier study by Matsumoto et al. [26] Heating protocol was 95°C for 5 min, followed by 40 cycles at 95°C for 30 s, 60°C for 30 s, and acquiring was in annealing/extension step. 
Statistical procedures
results
Patients
From 2012 to 2016, 291 patients with HTLV-1 symptoms (malignancy, neurological disease, strongyloidiasis, and bronchiectasis) were diagnosed by specialists and referred to hospitals affiliated to the Iran University of Medical Sciences, Tehran, Iran. The mean age of the patients was 38 ± 15 years and 123 (42.3%) were male and 168 (57.7%) were female. One hundred and twenty-seven samples were collected in a 5-mL tube containing EDTA, and RNA was extracted from PBMC using Ficoll gradient method. Also, 164 CSF samples (2.5 mL) were collected from the C7-T1 interspace in each patient using 2% gauge spinal needles [ Table 2 ].
Reverse transcriptase polymerase chain reaction and viral load
The RT-PCR assay showed that of 291 samples, 93 (31.9%) were positive for HTLV-1 tax gene [ Figure 1 ]. The mean age of positive patients was 40 ± 12 years (range, 18-74 years), and further characteristics are described in Table 3 . Majority of positive samples included PBMCs (77.4%). 
dIscussIon
To find out how XMRV infection causes any disease in the human population, it is important to detect this virus particle in clinical samples in different complications. [27] In this study, we investigated the presence of XMRV genome in WB (PBMC) and CSF of patients who were HTLV-1 positive for the first time in Iran.
Two hundred and ninety-one patients between 2012 and 2016 with HTLV symptoms were enrolled. Results show that from 291 WB (PBMC) and CSF samples, 93 (31.9%) were positive for HTLV-1 by RT-PCR method. For the evaluation of viral load, quantitative PCR (qPCR) was performed in positive patients that ranged between 2,655 and 120,867 IU/mL. In the next step, 93 HTLV-1-positive samples for the presence of the XMRV were investigated. Results showed one WB sample was positive for this virus, which suggests that XMRV is uncommon in this population-based cohort.
Researchers in the United States estimated frequency of XMRV in patients with prostate cancer (10%-27%) for the first time. It was suggested that XMRV prevalence in patients with CFS and patients with prostate cancer carrying a homozygous R462Q mutation in the RNaseL gene is 67% and 40%, respectively. [2, 8, 16, 24, 28] In the study by Qiu et al., [18] XMRV prevalence in 486 HTLV-infected Japanese patients was evaluated by chemiluminescence immunoassays (CMIAs) and RT-PCR methods. Results showed p15E antibodies detected by CMIA method in 20 (4.1%) samples, but no XMRV pol or env sequences were detected in these seroreactive samples by RT-PCR. The present study that performed just RT-PCR method for XMRV genome detection, notified the need to another confirmatory procedure to validate results. In 2017, Baig et al. [29] attempted to investigate the possible association between the XMRV infection and different variants of ductal prostate adenocarcinoma. The results showed that the XMRV DNA was detected in four of eight (50%) ductal adenocarcinomas. [29] In another cross-sectional survey in 2017 by Vasefi et al., [1] frequency of XMRV genome in 150 Iranian HIV-infected patients was evaluated. Their results showed that 13 (8.6%) plasma samples were positive for XMRV using real-time RT-PCR. In the current study, although there were quality checking in every steps, the method of detection probably had effects on the low infection frequency findings. Different complications of patients who infected by HIV and HTLV-1 might be another term to seen the reduced infection rates of our studied population.
There are several possible explanations for the discrepancy between our study and some previous studies, including that XMRV in fact does not establish infection in human peripheral blood at detectable levels, and the geographic differences between the cohort studies are critical. [30, 31] This is obvious in our research for which the majority of positive results were detected in PBMCs, although CSF specimens were more than PBMCs and it was not significant statistically. As the majority of studies detected XMRV sequences in North American patients, geographical distribution may play an important role in virus prevalence. [32, 33] There were some limitations in this study, including small sample size, applying highly sensitive or confirmatory techniques, and not using several primers to detect other XMRV genes, which need to be taken into account in future studies, although this was an only preliminary study in Iranian patients with HTLV-1. On the basis of our results, we found that the prevalence of XMRV infection is low among patients who acquire HTLV-1 infection. This study showed that the individuals at risk for HTLV-1 infection are not at risk for XMRV infection.
conclusIon
In this study, we failed to find any significant correlation between XMRV infection and HTLV-1 complications. In view of these negative findings in this highly susceptible group, we conclude that it is unlikely that XMRV or related viruses are circulating at a significant level in patients who are HTLV-1 positive in Tehran, Iran.
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